Literature DB >> 22205645

Domain III regulates N-type (CaV2.2) calcium channel closing kinetics.

Viktor Yarotskyy1, Guofeng Gao, Blaise Z Peterson, Keith S Elmslie.   

Abstract

Ca(V)2.2 (N-type) and Ca(V)1.2 (L-type) calcium channels gate differently in response to membrane depolarization, which is critical to the unique physiological functions mediated by these channels. We wondered if the source for these differences could be identified. As a first step, we examined the effect of domain exchange between N-type and L-type channels on activation-deactivation kinetics, which were significantly different between these channels. Kinetic analysis of chimeric channels revealed N-channel-like deactivation for all chimeric channels containing N-channel domain III, while activation appeared to be a more distributed function across domains. This led us to hypothesize that domain III was an important regulator of N-channel closing. This idea was further examined with R-roscovitine, which is a trisubstituted purine that slows N-channel deactivation by exclusively binding to activated N-channels. L-channels lack this response to roscovitine, which allowed us to use N-L chimeras to test the role of domain III in roscovitine modulation of N-channel deactivation. In support of our hypothesis, all chimeric channels containing the N-channel domain III responded to roscovitine with slowed deactivation, while those chimeric channels with L-channel domain III did not. Thus a combination of kinetic and pharmacological evidence supports the hypothesis that domain III is an important regulator of N-channel closing. Our results support specialization of gating functions among calcium channel domains.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205645      PMCID: PMC3331666          DOI: 10.1152/jn.00993.2011

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  54 in total

Review 1.  Structure and regulation of voltage-gated Ca2+ channels.

Authors:  W A Catterall
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

2.  Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel.

Authors:  H Saegusa; T Kurihara; S Zong; A Kazuno ; Y Matsuda; T Nonaka; W Han; H Toriyama; T Tanabe
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

3.  Chemical inhibitors of cyclin-dependent kinases.

Authors:  L Meijer
Journal:  Trends Cell Biol       Date:  1996-10       Impact factor: 20.808

Review 4.  Calcium channel blockers in the treatment of disease.

Authors:  Keith S Elmslie
Journal:  J Neurosci Res       Date:  2004-03-15       Impact factor: 4.164

5.  Restoration of inactivation in mutants of Shaker potassium channels by a peptide derived from ShB.

Authors:  W N Zagotta; T Hoshi; R W Aldrich
Journal:  Science       Date:  1990-10-26       Impact factor: 47.728

6.  FPL 64176 modification of Ca(V)1.2 L-type calcium channels: dissociation of effects on ionic current and gating current.

Authors:  Stefan I McDonough; Yasuo Mori; Bruce P Bean
Journal:  Biophys J       Date:  2004-10-22       Impact factor: 4.033

7.  Determination of the subunit stoichiometry of a voltage-activated potassium channel.

Authors:  R MacKinnon
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

8.  Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons.

Authors:  Zhen Yan; Ping Chi; James A Bibb; Timothy A Ryan; Paul Greengard
Journal:  J Physiol       Date:  2002-05-01       Impact factor: 5.182

9.  Cloning and deletion mutagenesis of the alpha2 delta calcium channel subunit from porcine cerebral cortex. Expression of a soluble form of the protein that retains [3H]gabapentin binding activity.

Authors:  J P Brown; N S Gee
Journal:  J Biol Chem       Date:  1998-09-25       Impact factor: 5.157

10.  Roscovitine differentially affects CaV2 and Kv channels by binding to the open state.

Authors:  Zafir Buraei; Geoffrey Schofield; Keith S Elmslie
Journal:  Neuropharmacology       Date:  2006-11-27       Impact factor: 5.250

View more
  4 in total

1.  Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist.

Authors:  Sulan Luo; Dongting Zhangsun; Peta J Harvey; Quentin Kaas; Yong Wu; Xiaopeng Zhu; Yuanyan Hu; Xiaodan Li; Victor I Tsetlin; Sean Christensen; Haylie K Romero; Melissa McIntyre; Cheryl Dowell; James C Baxter; Keith S Elmslie; David J Craik; J Michael McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

2.  New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease.

Authors:  Man Wu; Hayley V White; Blake A Boehm; Christopher J Meriney; Kaylan Kerrigan; Michael Frasso; Mary Liang; Erika M Gotway; Madeleine R Wilcox; Jon W Johnson; Peter Wipf; Stephen D Meriney
Journal:  Neuropharmacology       Date:  2017-12-12       Impact factor: 5.250

3.  α-Neurexins Together with α2δ-1 Auxiliary Subunits Regulate Ca2+ Influx through Cav2.1 Channels.

Authors:  Johannes Brockhaus; Miriam Schreitmüller; Daniele Repetto; Oliver Klatt; Carsten Reissner; Keith Elmslie; Martin Heine; Markus Missler
Journal:  J Neurosci       Date:  2018-08-13       Impact factor: 6.167

4.  Regulation of neuronal cav3.1 channels by cyclin-dependent kinase 5 (Cdk5).

Authors:  Aida Calderón-Rivera; Alejandro Sandoval; Ricardo González-Ramírez; Christian González-Billault; Ricardo Felix
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.